From the *Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland; †The EMMES Corporation, Rockville, Maryland; ‡Beetham Eye Institute, Joslin Diabetes Center and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; §Texas Retina Associates, Dallas, Texas; ¶Department of Ophthalmology, University of Wisconsin, Madison, Wisconsin; **Wilmer Eye Institute, Baltimore, Maryland (now at Will's Eye Philadelphia, Pennsylvania); ††Emory Eye Center, Atlanta, Georgia (now at Department of Ophthalmology, Cleveland Eye Clinic, Cleveland, Ohio); and ‡‡California Retina Consultants, Santa Barbara, California.
Supported by the National Eye Institute or National Institutes of Health intramural program. The study medication and funds for the examinations of the participants enrolled in the extramural clinics were provided by Pharmacia.
Reprint requests: Emily Y. Chew, MD, National Institutes of Health, Building 10, CRC, Room 3-2531, 10 Center Drive, MSC 1204, Bethesda, MD 20892-1204; e-mail: [email protected]
